I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
ADME-Tox - An Introduction
Toxicology Testing
ADME Testing
II. EXECUTIVE SUMMARY
1. OUTLOOK
ADME-Tox Testing Gains Traction
A Peek into the Impact of ADME-Tox Screening on New Drug Discovery
Table 1: Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics (includes corresponding Graph/Chart)
Table 2: Factors Leading to Failure of Drugs in Phase II Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others (includes corresponding Graph/Chart)
Table 3: Factors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others (includes corresponding Graph/Chart)
Table 4: Drug Withdrawals Due to Toxicity Issues (1990-2010): Percentage Share Breakdown of Number of Drugs Withdrawn Due to Cardiotoxicity, Hepatotoxicity and Others (includes corresponding Graph/Chart)
Current and Future Analysis
US and Europe Dominate, Asia-Pacific Lends Growth Momentum
Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge
2. INDUSTRY OVERVIEW
Pharma Industry Renews Focus on Cost Optimization
Table 5: US R&D Productivity Trends in Pharma Industry (2006- 2015) (includes corresponding Graph/Chart)
China and India: Hot Spots for R&D Investment
Table 6: World R&D Market by Geographic Region (2015 & 2016): Percentage Breakdown of R&D Spending for Asia, Europe, Middle East & Africa, North America and South America (includes corresponding Graph/Chart)
Table 7: World Life Science R&D Spending by Geographic Region (2015 & 2016): Spending in US$ Billion for US and Rest of World (includes corresponding Graph/Chart)
ADME-Tox Assays - An Overview
Introduction of Early In Vitro ADMET Studies
Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
Table 8: World Cell-based Assays Market by Segment (2016): Percentage Breakdown of Revenue for Products and Services (includes corresponding Graph/Chart)
Table 9: World Cell-based Assays Market by Application (2016): Percentage Breakdown of Revenue for ADME, Basic Research and Drug Discovery (includes corresponding Graph/Chart)
Table 10: Global Market for Cell-based Assays (2016): Percentage Breakdown of Value Sales by End-User (includes corresponding Graph/Chart)
Major Types of Cell-Based HTS Assays for Drug Screening
CROs Expand Presence
Drug Discovery Outsourcing and Type of Services Outsourced
Changing Face of Drug Discovery Outsourcing Activity
M&A - Order of the Day
3. MARKET DYNAMICS
Current State of ADME-Tox Testing
Need for Better Models: A Major Factor Driving Innovation in the Market
Focus Shifts to Innovative Approaches
In Silico and In Vitro- the Way to Go
In Vitro Testing Systems and Its Relevance in Drug Development
Growing Inclination towards In-vitro Assays for Toxicology Studies
In Silico ADME-Tox Growing at a Fast Clip
Advantages of Using In Silico Approaches
Factors Hindering Growth
3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
Rising Number of Drug Targets Surge Demand for Cell-Based Assays
Growing Focus on the Development of Reproducible and Robust Cell-based Assays
Functional Assays: An Effective Way of Predicting Specific Toxic Effects
GPCR Targets to Drive Growth in Functional Cell Assay Market
New Alternatives for Early-Stage Toxicology Testing
Stem Cells Exude Great Potential in Drug Toxicity Testing
Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism
Improved Cryopreservation Technologies Help Expand Use of Hepatocytes
Cardiotoxicity Testing Gains Prominence
Cell Imaging-Gaining Popularity
In Vivo Imaging Persists in ADME-Tox Testing
Computational Models on Rise
Adoption of Data Management Systems
Drug Transporter Analysis Becoming Part of ADME Assessment
Slow Metabolism of Novel Drugs Call for More Human Models in Screening
Further Advances Required for More Understanding of Biotransformation
Introduction of Third Dimension in Cell Culturing Drives Need for New Instrumentation
Regulatory Bodies Focus on Transporter Mediated DDIs
4. DRUG DISCOVERY & DEVELOPMENT
Overview
Table 11: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
Drug Discovery and Development
Target identification
Target Validation
Lead Identification
Lead Optimization
Pharmaceuticals - R&D Value Chain
Pre-Clinical Testing
Clinical Trials
Clinical Trials - The Time Line
Drug Discovery Technologies
Innovation in Screening Guarantees Success for Drug Discovery Programs
5. PRODUCT OVERVIEW
ADME-Tox - An Introduction
Absorption
Distribution
Metabolism
Excretion
Toxicity
ADME-Tox Profiling
ADME-Tox Screening Technologies
ADME-Tox Parameters
Cell Based Assays
Liver Cell Based Assays
Intestinal Cell Based Assays
Kidney Cell Based Assays
6. PRODUCT INNOVATIONS/INTRODUCTIONS
Corning Adds Two New Products to ADME/Tox Lineup
Sovicell and 3B Pharmaceuticals Launch EScalate Assay Service
Lonza Launches Human and Animal Hepatocytes for Adme-Tox Testing
Cyprotex Launches Eight New Transporter Assays
Simulations Plus Rolls Out Version 8.0 of ADMET Predictor™ Software
Simulations Plus Launches Version 7.2 of ADMET Predictor™ Software
BioReliance® Unveils Select In Vitro ADME and Toxicology Testing Services
Cyprotex Releases SenCeeTox® Technology with Enhanced Capabilities
Cyprotex Expands In-House Drug Transporter Services
Cyprotex Launches KeratinoSens™ Service
Simulations Plus Introduces ADMET Predictor Version 7.1
Lena Biosciences Launches SeedEZ 3D Cell Culture Products
Sigma® Life Science to Introduce Genetically-Modified HepaRG™ Human Liver Cell Line
7. RECENT INDUSTRY ACTIVITY
Simulations Plus to Take Over DILIsym Services
Simulations Plus and Electrolab India Sign Distribution Deal
Simulations Plus Inks Distribution Deal with Quantum Bio Solutions for Korean Market
Cyprotex Moves to New Location in the UK
Pharmaron Takes Over Xceleron
Evotec Acquires Cyprotex
Endonovo Expands Cytotronics Platform for Toxicology Testing
Takara Bio Acquires Cellectis AB
WuXi PharmaTech Acquires XenoBiotic Laboratories
Merck KGaA to Take Over Sigma-Aldrich
Dassault Systèmes Acquires Accelrys
Organovo Collaborates with J&J for 3D Bioprinting Drug Discovery Research
Taconic and IVAL Enter into Agreement
Charles River to Acquire Galapagos' Argenta and BioFocus Service Divisions
Simulations Plus Signs 5-Year RCA with the US FDA
Simulation Plus Inks Distributor Agreement with RILD
Harlan CRS Enters into Strategic Alliance with Bertin Pharma
Pharmaron Receives GLP Certification from the CFDA for GLP Toxicology Facilities
Cyprotex Acquires CeeTox
Taconic Announces Name Change
Rosa & Co. Acquires Entelos Holdings' Consulting Service Business
Thermo Fisher Scientific Acquires Life Technologies
8. FOCUS ON SELECT PLAYERS
ACEA Biosciences, Inc. (USA)
ADMEcell, Inc. (USA)
Agilent Technologies, Inc. (USA)
Albany Molecular Research, Inc. (USA)
Beckman Coulter, Inc. (USA)
BioreclamationIVT, LLC (USA)
Cerep SA (France)
CompuDrug International, Inc. (USA)
Cyprotex PLC. (UK)
CeeTox, Inc. (USA)
Dassault Systèmes Biovia Corp. (USA)
Eurofins ADME BIOANALYSES SAS (France)
Galapagos NV (Belgium)
Molecular Discovery Ltd. (UK)
MultiCASE, Inc. (USA)
Optivia Biotechnology (USA)
PerkinElmer, Inc. (USA)
Pharmaron, Inc. (USA)
Promega Corporation (USA)
Qualyst, Inc. (USA)
Simulations Plus, Inc. (USA)
Taconic Biosciences, Inc. (USA)
Takara Bio Europe AB (Sweden)
Tecan Group Ltd. (Switzerland)
Thermo Fisher Scientific, Inc. (USA)
9. GLOBAL MARKET PERSPECTIVE
Table 12: World Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 13: World Historic Review for ADME-Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 14: World 14-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 15: World Recent Past, Current & Future Analysis for Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 16: World Historic Review for Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 17: World 14-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 18: World Recent Past, Current & Future Analysis for Toxicology Testing by Segment - In-Vivo and In-Vitro Toxicology Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 19: World Historic Review for Toxicology Testing by Segment - In-Vivo and In-Vitro Toxicology Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 20: World 14-Year Perspective for Toxicology Testing by Segment - Percentage Breakdown of Revenues for In-Vivo and In-Vitro Toxicology Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 21: World Recent Past, Current & Future Analysis for In-Vivo Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 22: World Historic Review for In-Vivo Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 23: World 14-Year Perspective for In-Vivo Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 24: World Recent Past, Current & Future Analysis for In-Vitro Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 25: World Historic Review for In-Vitro Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 26: World 14-Year Perspective for In-Vitro Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 27: World Recent Past, Current & Future Analysis for ADME Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 28: World Historic Review for ADME Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 29: World 14-Year Perspective for ADME Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A.Market Analysis
Current & Future Analysis
Clinical Trials Market in the US
Key Statistics
Table 30: Leading Toxicology Testing Laboratories in the US (2016): Percentage Breakdown of Revenue for Alere Toxicology, Medytox Solutions, Quest Diagnostics and Others (includes corresponding Graph/Chart)
Product/Service Launches
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 31: US Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 32: US Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 33: US 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
2. CANADA
Market Analysis
Table 34: Canadian Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 35: Canadian Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 36: Canadian 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
3. JAPAN
Market Analysis
Table 37: Japanese Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 38: Japanese Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 39: Japanese 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4. EUROPE
A.Market Analysis
Current & Future Analysis
Clinical Trials Market in Europe
B.Market Analytics
Table 40: European Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 41: European Historic Review for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 42: European 14-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 43: European Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 44: European Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 45: European 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4a. FRANCE
A.Market Analysis
Current & Future Scenario
Key Players
B.Market Analytics
Table 46: French Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 47: French Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 48: French 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4b. GERMANY
A.Market Analysis
Current & Future Analysis
Product Launch
Strategic Corporate Development
B.Market Analytics
Table 49: German Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 50: German Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 51: German 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 52: Italian Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 53: Italian Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 54: Italian 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A.Market Analysis
Current & Future Analysis
Product/Service Launches
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 55: UK Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 56: UK Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 57: UK 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4e. SPAIN
A.Market Analysis
Current & Future Analysis
Garnering Investments from Multinational Pharma Companies
Table 58: Apportion of R & D Expenditure by Study Phase in Spain: 2015 (includes corresponding Graph/Chart)
B.Market Analytics
Table 59: Spanish Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 60: Spanish Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 61: Spanish 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4f. REST OF EUROPE
A.Market Analysis
Current & Future Analysis
Clinical Trials Market in Select Regions
Russia
Table 62: Russian Clinical Trials Market by Trial Type (2015): Percentage Breakdown of Number of Trials for Bioequivalence Studies (Foreign Sponsors), Bioequivalence Studies (Local Sponsors), Global Multi-Center Clinical Trials, Local Clinical Trials (Foreign Sponsors), and Local Clinical Trials (Local Sponsors) (includes corresponding Graph/Chart)
Table 63: Russian Clinical Trials Market Volume (2015): Percentage Breakdown of Trials by Hosting Country (includes corresponding Graph/Chart)
Product Launch
Strategic Corporate Development
Key Players
B.Market Analytics
Table 64: Rest of Europe Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 65: Rest of Europe Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 66: Rest of Europe 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
A.Market Analysis
Current & Future Analysis
Asia: The Most Preferred Destination for Clinical Trials
An Overview of Clinical Trials Market in Select Countries in The Region
China
Pharmaceutical Outsourcing Sector in China- An Overview
Implementation of GLP Standard Makes Data Internationally Acceptable
Use of Non-Human Primates- A Key Feature of Chinese Pharmaceutical Sector
Going Ahead....
India
A Thriving Clinical Trials Market
Table 67: Cost of Conducting Clinical Trials: India Vs. US (In US$ Thousand) (includes corresponding Graph/Chart)
Australia
Australia Makes Strong Pitch for Clinical Trials
Major Challenges Facing Australian Clinical Trials Market
Strategic Corporate Developments
B.Market Analytics
Table 68: Asia-Pacific Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 69: Asia-Pacific Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 70: Asia-Pacific 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
6. REST OF WORLD
A.Market Analysis
Current & Future Analysis
Latin America: An Emerging Market for Clinical Trials
The Middle East - Brimming with Potential for Clinical Trials
Table 71: The Middle East Clinical Trial Market (2015): Percentage Breakdown of Registered Clinical Trials in Iran, Israel, Turkey and Rest of Middle East (includes corresponding Graph/Chart)
B.Market Analytics
Table 72: Rest of World Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 73: Rest of World Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 74: Rest of World 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 69 (including Divisions/Subsidiaries - 77) The United States (46) Canada (2) Japan (1) Europe (24) - France (4) - Germany (3) - The United Kingdom (6) - Spain (1) - Rest of Europe (10) Asia-Pacific (Excluding Japan) (4)
